Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 653 Cr.
- Current Price ₹ 14.9
- High / Low ₹ 27.2 / 5.75
- Stock P/E 68.2
- Book Value ₹ 1.44
- Dividend Yield 0.67 %
- ROCE 21.8 %
- ROE 15.9 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 244% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.6%
- Debtor days have improved from 135 to 98.2 days.
Cons
- Stock is trading at 10.4 times its book value
- Working capital days have increased from 208 days to 415 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4.44 | 2.60 | 4.82 | 5.14 | 5.34 | 5.66 | 11.84 | 11.18 | 20.48 | 58.83 | 74.57 | 32.59 | |
4.54 | 2.85 | 3.64 | 3.68 | 3.73 | 4.01 | 10.30 | 9.74 | 17.59 | 53.47 | 55.17 | 19.87 | |
Operating Profit | -0.10 | -0.25 | 1.18 | 1.46 | 1.61 | 1.65 | 1.54 | 1.44 | 2.89 | 5.36 | 19.40 | 12.72 |
OPM % | -2.25% | -9.62% | 24.48% | 28.40% | 30.15% | 29.15% | 13.01% | 12.88% | 14.11% | 9.11% | 26.02% | 39.03% |
0.19 | 1.12 | -0.38 | 0.07 | 0.11 | 0.04 | 0.11 | 0.16 | 0.08 | 1.20 | 2.82 | 4.21 | |
Interest | 0.01 | 0.00 | 0.00 | 0.01 | 0.04 | 0.00 | 0.00 | 0.03 | 0.29 | 0.28 | 0.29 | 0.59 |
Depreciation | 0.78 | 0.60 | 0.45 | 0.47 | 0.74 | 0.96 | 1.48 | 1.47 | 1.66 | 1.84 | 2.05 | 3.00 |
Profit before tax | -0.70 | 0.27 | 0.35 | 1.05 | 0.94 | 0.73 | 0.17 | 0.10 | 1.02 | 4.44 | 19.88 | 13.34 |
Tax % | 8.57% | 51.85% | 65.71% | 52.38% | 44.68% | 36.99% | 82.35% | -90.00% | 26.47% | 0.90% | 6.74% | 28.19% |
-0.76 | 0.13 | 0.12 | 0.50 | 0.53 | 0.46 | 0.04 | 0.19 | 0.75 | 4.41 | 18.54 | 9.58 | |
EPS in Rs | -0.02 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.10 | 0.42 | 0.22 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 15.70% | 14.81% | 17.07% | 0.00% | 0.00% | 10.47% | 4.43% | 5.91% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 29% |
5 Years: | 22% |
3 Years: | 17% |
TTM: | -56% |
Compounded Profit Growth | |
---|---|
10 Years: | 53% |
5 Years: | 244% |
3 Years: | 134% |
TTM: | -48% |
Stock Price CAGR | |
---|---|
10 Years: | 49% |
5 Years: | 154% |
3 Years: | 217% |
1 Year: | 35% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 22% |
3 Years: | 27% |
Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 3.91 | 10.95 | 43.79 |
Reserves | 12.26 | 12.39 | 12.51 | 13.01 | 13.44 | 13.81 | 13.85 | 14.03 | 14.78 | 21.38 | 46.69 | 19.05 |
0.31 | 1.20 | 0.04 | 0.04 | 3.58 | 6.06 | 8.05 | 9.77 | 3.38 | 5.08 | 3.16 | 4.17 | |
4.10 | 3.15 | 3.16 | 4.32 | 5.51 | 6.95 | 10.07 | 10.24 | 15.39 | 44.60 | 17.04 | 19.76 | |
Total Liabilities | 18.24 | 18.31 | 17.28 | 18.94 | 24.10 | 28.39 | 33.54 | 35.61 | 35.12 | 74.97 | 77.84 | 86.77 |
9.58 | 9.72 | 9.67 | 10.17 | 14.12 | 15.60 | 17.38 | 17.69 | 17.58 | 20.23 | 19.94 | 19.39 | |
CWIP | 1.66 | 1.68 | 1.68 | 1.64 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.95 |
Investments | 0.05 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
6.95 | 6.88 | 5.89 | 7.09 | 8.27 | 11.08 | 14.45 | 16.07 | 15.88 | 53.08 | 56.24 | 65.43 | |
Total Assets | 18.24 | 18.31 | 17.28 | 18.94 | 24.10 | 28.39 | 33.54 | 35.61 | 35.12 | 74.97 | 77.84 | 86.77 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-2.90 | -2.03 | 2.72 | -0.29 | 0.84 | 0.26 | 1.24 | 0.54 | 7.99 | 3.17 | -5.20 | 7.92 | |
-10.16 | 0.73 | -0.41 | -0.93 | -4.75 | -2.45 | -3.36 | -1.89 | -1.53 | -4.43 | -1.20 | -1.26 | |
-18.43 | 1.38 | -1.16 | 0.00 | 3.45 | 2.38 | 1.99 | 1.74 | -6.68 | 4.94 | 12.41 | -4.52 | |
Net Cash Flow | -31.49 | 0.08 | 1.15 | -1.22 | -0.46 | 0.18 | -0.12 | 0.38 | -0.21 | 3.68 | 6.01 | 2.14 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 45.21 | 73.00 | 71.18 | 175.40 | 200.27 | 345.01 | 245.08 | 318.31 | 131.88 | 187.31 | 119.97 | 98.22 |
Inventory Days | 133.79 | 553.65 | 91.77 | 112.31 | 53.23 | 99.55 | 169.12 | 221.37 | 139.30 | 25.45 | 18.96 | 447.26 |
Days Payable | 208.91 | 291.18 | 108.46 | 400.10 | 733.80 | 1,161.36 | 785.97 | 702.33 | 302.93 | 270.77 | 59.25 | 414.45 |
Cash Conversion Cycle | -29.90 | 335.47 | 54.50 | -112.39 | -480.30 | -716.81 | -371.77 | -162.64 | -31.75 | -58.01 | 79.68 | 131.04 |
Working Capital Days | 368.29 | 758.08 | 258.23 | 343.70 | 379.35 | 439.81 | 225.97 | 278.48 | 61.49 | 49.01 | 159.57 | 415.40 |
ROCE % | -5.71% | -0.96% | 6.28% | 7.38% | 5.90% | 3.65% | 0.31% | 1.35% | 5.81% | 18.84% | 44.25% | 21.80% |
Documents
Announcements
- Corporate Action-Board approves Dividend 4 Jun
-
Board Meeting Outcome for Outcome Of The Meeting Of The Board Held On Wednesday, June 04, 2025
4 Jun - Board recommends final dividend of Rs.0.01/share for FY 2024-25, subject to shareholder approval.
-
Board Meeting Intimation for Meeting Of The Board Of The Company Is Scheduled To Be Held On 04Th June 2025
31 May - Board meeting on 14 June 2025 to declare final dividend for FY 2024-25.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Publication of Results for the quarter and year ended 31/03/2025
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Secretarial compliance report FY25; minor fines for late filings; share capital increase; director and CFO changes.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies